Cargando…

Intraperitoneal injection of class A TLR9 agonist enhances anti–PD-1 immunotherapy in colorectal peritoneal metastases

Peritoneal metastases are associated with a low response rate to immune checkpoint blockade (ICB) therapy. The numbers of peritoneal resident macrophages (PRMs) are reversely correlated with the response rate to ICB therapy. We have previously shown that TLR9 in fibroblastic reticular cells (FRCs) p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Ting, Zhang, Hongji, Li, Yiming, Jayakumar, Preethi, Liao, Hong, Huang, Hai, Billiar, Timothy R., Deng, Meihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714777/ https://www.ncbi.nlm.nih.gov/pubmed/36278484 http://dx.doi.org/10.1172/jci.insight.160063

Ejemplares similares

GATA6(+) Peritoneal Resident Macrophage: The Immune Custodian in the Peritoneal Cavity
por: Jayakumar, Preethi, et al.
Publicado: (2022)

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma
por: Zhou, Zhimei, et al.
Publicado: (2021)

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis
por: Thadi, Anusha, et al.
Publicado: (2018)

Experimental intraperitoneal injection of alcohol in rats: Peritoneal findings and histopathology
por: In, Hyun Sin, et al.
Publicado: (2014)

Treatment Response After Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases of Colorectal Originf
por: Hübner, Martin, et al.
Publicado: (2022)

Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer
por: Spiegelberg, Julia, et al.
Publicado: (2020)

Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer
por: Takahashi, Kazuya, et al.
Publicado: (2022)

Management of peritoneal surface metastases from colorectal cancer: Cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, pressurized intraperitoneal chemotherapy, and beyond
por: Mangieri, Christopher W., et al.
Publicado: (2022)

Cytoreduction surgery and hyperthermic intraperitoneal chemotherapy for treating advanced peritoneal metastases of hepatocellular carcinoma
por: Hung, Kuo-Chen, et al.
Publicado: (2020)

Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy
por: Ubink, I., et al.
Publicado: (2019)

The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
por: Wong, Jolene Si Min, et al.
Publicado: (2020)

Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives
por: Christou, Niki, et al.
Publicado: (2021)

Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases
por: Balmer, Aurélie, et al.
Publicado: (2022)

Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment
por: Smith, Anton A. A., et al.
Publicado: (2020)

Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
por: White, Michael G., et al.
Publicado: (2020)

Thermosensitive Injectable Hydrogel for Simultaneous Intraperitoneal Delivery of Doxorubicin and Prevention of Peritoneal Adhesion
por: Chen, Chih-Hao, et al.
Publicado: (2018)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
por: Zhang, Hongji, et al.
Publicado: (2021)

Role of laparoscopy in patients with peritoneal metastases considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
por: Jayakrishnan, Thejus T, et al.
Publicado: (2014)

The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2017)

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer
por: Cornali, Tommaso, et al.
Publicado: (2017)

Immune response activation following hyperthermic intraperitoneal chemotherapy for peritoneal metastases: A pilot study
por: Fiorentini, Giammaria, et al.
Publicado: (2020)

Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases
por: Shi, Min, et al.
Publicado: (2021)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Where do we stand?
por: Witmer, Hunter D. D., et al.
Publicado: (2022)

Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
por: Yang, Haitang, et al.
Publicado: (2020)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2021)

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases in Solid Organ Graft Recipients: First Experience
por: Horvath, Philipp, et al.
Publicado: (2019)

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Summary of Key Clinical Trials
por: Turner, Kevin M., et al.
Publicado: (2022)

The Role of Prophylactic and Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Prevention of Peritoneal Metastases in Advanced Colorectal Cancer
por: Sun, Beatrice J., et al.
Publicado: (2023)

Note on Intraperitoneal Injections
por: Durham, Herbert E.
Publicado: (1897)

Response to Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
por: White, Michael G., et al.
Publicado: (2020)

Liposomal Resiquimod for Enhanced Immunotherapy of Peritoneal Metastases of Colorectal Cancer
por: Pauli, Griffin, et al.
Publicado: (2021)

Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab
por: Goéré, Diane, et al.
Publicado: (2014)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Cytoreductive Surgery and Normothermic Intraperitoneal Chemotherapy for Signet Ring Cell Appendiceal Adenocarcinoma With Peritoneal Metastases in the Setting of Cirrhosis
por: Panuganti, Bharat, et al.
Publicado: (2018)

Hyperthermic intraperitoneal chemotherapy with cisplatin and mitomycin C for colorectal cancer peritoneal metastases: A systematic review of the literature
por: Pinto, Amandine, et al.
Publicado: (2019)

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer
por: Rezniczek, Günther A., et al.
Publicado: (2020)

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes
por: Rosa, Fausto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ikmitc7n88cdnqujsqvs8r5rgk